These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32885992)

  • 21. Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy.
    Binstock ML; Mundy GR
    Ann Intern Med; 1980 Aug; 93(2):269-72. PubMed ID: 7406378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pamidronate and calcitonin as therapy of acute cancer-related hypercalcemia in children.
    Schmid I; Stachel D; Schön C; Bauer M; Haas RJ
    Klin Padiatr; 2001; 213(1):30-4. PubMed ID: 11225473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pamidronate in the treatment of tumor-associated hypercalcemia].
    Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
    Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A combination of calcitonin and bisphosphonate for the emergency treatment of severe tumor-induced hypercalcemia.
    Luce K; O'Donnell DE; Morton AR
    Calcif Tissue Int; 1993 Jan; 52(1):70-1. PubMed ID: 8453509
    [No Abstract]   [Full Text] [Related]  

  • 25. Conventional treatment of hypercalcemia of malignancy.
    Davidson TG
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S8-15. PubMed ID: 11757206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of hypercalcemia of malignancy with bisphosphonates.
    Berenson JR
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
    Pecherstorfer M; Herrmann Z; Body JJ; Manegold C; Degardin M; Clemens MR; Thürlimann B; Tubiana-Hulin M; Steinhauer EU; van Eijkeren M; Huss HJ; Thiébaud D
    J Clin Oncol; 1996 Jan; 14(1):268-76. PubMed ID: 8558208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of hypercalcaemia of malignancy.
    Heath DA
    Baillieres Clin Endocrinol Metab; 1990 Mar; 4(1):139-45. PubMed ID: 2143893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of malignancy associated hypercalcemia].
    Tai N; Inoue D
    Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on the medical treatment of hypercalcemia of malignancy.
    Hall TG; Schaiff RA
    Clin Pharm; 1993 Feb; 12(2):117-25. PubMed ID: 8453860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy.
    Kim S
    J Oncol Pharm Pract; 2019 Oct; 25(7):1787-1793. PubMed ID: 30419769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Combination therapy with pamidronate and calcitonin in hypercalcemic crisis caused by primary hyperparathyroidism].
    Christensen JH; Kristiansen JH
    Ugeskr Laeger; 1992 Nov; 154(47):3341-2. PubMed ID: 1462441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
    Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
    Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
    Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative tolerability of drug therapies for hypercalcaemia of malignancy.
    Zojer N; Keck AV; Pecherstorfer M
    Drug Saf; 1999 Nov; 21(5):389-406. PubMed ID: 10554053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Symptomatic hypocalcemia following combined calcitonin and mithramycin therapy for hypercalcemia due to malignancy.
    Caro JF; Besarab A; Glennon JA
    Cancer Treat Rep; 1978 Oct; 62(10):1561-3. PubMed ID: 152145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of acute lymphoblastic leukemia-induced extreme hypercalcemia with pamidronate and calcitonin.
    Mathur M; Sykes JA; Saxena VR; Rao SP; Goldman GM
    Pediatr Crit Care Med; 2003 Apr; 4(2):252-5. PubMed ID: 12749663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Malignancy-associated hypercalcemia].
    Oura S
    Nihon Rinsho; 2003 Jun; 61(6):1006-9. PubMed ID: 12806951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.
    El-Hajj Fuleihan G; Clines GA; Hu MI; Marcocci C; Murad MH; Piggott T; Van Poznak C; Wu JY; Drake MT
    J Clin Endocrinol Metab; 2023 Feb; 108(3):507-528. PubMed ID: 36545746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.